With the ultimate goal of developing a novel treatment for multiple sclerosis (MS), we have developed a cell-based gene therapy protocol for the treatment of murine experimental autoimmune encephalomyelitis (EAE), a powerful animal model for MS. We have determined that transduced fibroblasts secreting encephalogenic epitopes, when injected into mice with EAE, cause a striking abrogation of disease. Both myelin basic protein (MBP) and proteolipid protein mini-gene constructs expressed in syngeneic fibroblast cells were capable of ameliorating ongoing EAE induced by MBP protein. These experiments are crucial since they suggest that not all encephalogenic epitopes need be secreted for the control of disease. We also demonstrate the success of this protocol when transduced syngeneic, and most importantly, allogeneic cells are sequestered within an implantable chamber. Furthermore, we find that through modifying antigen expression by changing the signal sequence of the mini-gene construct, we were able to significantly reduce the dose of cells required for treatment. These improvements to the minigene delivery system are critical for the eventual translation of our protocol to the clinic.
Introduction
Human gene therapy was initially conceived to treat genetic diseases by the introduction of the appropriate functional gene into cells. It now encompasses the treatment of complex acquired diseases such as cancer, cardiovascular ailments and autoimmune disorders. [1] [2] [3] [4] This report focuses on the development of a gene therapy strategy using cells engineered to deliver therapeutic molecules. The ultimate goal is to treat patients suffering from the most common autoimmune disease of the nervous system, multiple sclerosis (MS).
In MS the immune response attacks and destroys the myelin sheath that insulates central nervous system axons. [5] [6] [7] This can result in a wide variety of signs and symptoms such as paralysis, sensory defects and visual problems. The disease is normally diagnosed in young adulthood with women outnumbering men 2:1. 8 Its etiology is unknown, although environmental and genetic factors contribute to pathogenesis. Susceptibility genes have not been clearly identified, although the major histocompatibility complex HLA, particularly the DR2 haplotype, has been implicated. [9] [10] [11] [12] The pathology of disease is characterized by lymphocyte and mononuclear cell infiltrate in the brain and spinal cord. Much effort has been expended over the years to elucidate the mechanisms of immune dysfunction. It is generally believed that myelin-specific activated CD4 T cells secreting inflammatory cytokines (Th1 cells) play a significant role in orchestrating myelin destruction. 5, 13 Development of therapies aimed at specifically deleting or tolerizing (anergizing) these cells, so they no longer respond to myelin antigen, is the ultimate goal of this and other studies. [14] [15] [16] [17] [18] Murine experimental autoimmune encephalomyelitis (EAE) is considered to be a powerful animal model for the study of both the immunological mechanisms of myelin destruction and for the testing of potential therapies for MS. [19] [20] [21] The disease can be induced by injection of genetically susceptible animals with myelin proteins and closely resembles the course, clinical manifestations and pathology of relapsing and remitting MS. In female SJL/J mice used in this study, the first attack is mediated by CD4 T cells specific for proteolipid protein (PLP) amino acids 139-151. [22] [23] [24] In subsequent relapses, T cells specific for other encephalogenic epitopes, such as myelin basic protein (MBP) amino acids 84-104, have been demonstrated. 25, 26 This diversification of epitope specificity as disease progresses has been defined as epitope spreading. [27] [28] [29] In order to halt or ameliorate EAE disease in SJL/J mice, we have used a gene therapy approach in which continuous exposure to low levels of PLP antigen in the absence of a co-stimulatory signal -conditions believed to render T cells unresponsive -resulted in a striking abrogation of both clinical and histological signs of disease. To provide this therapeutic antigen-specific signal, we injected mice, suffering from EAE, after the initial acute attack, with syngeneic diploid fibroblast cells transduced with a retroviral vector designed to encode PLP 101-157 targeted for secretion. 30 With the goal of translation to the clinic, we now report the results of experiments in SJL/J mice designed to optimize this therapy for the treatment of MS. We show that our strategy is efficacious using a second epitope antigen, MBP 89-101. 31 This is of critical importance, since T cells responding to this epitope have been detected in many MS patients. 21, [32] [33] [34] [35] To address clinical practicality and safety concerns, we have sequestered the transduced cells within a chamber that is implanted subcutaneously (s.c.). Use of the chamber not only enables us to use allogeneic cells for treatment, thus allowing for development of a 'universal' treatment cell line, but also permits us to terminate the treatment should any exacerbation occur. Finally, by altering the signal sequence to increase antigen secretion, we have been able to significantly reduce the effective dose of transduced cells.
Results

EAE is abrogated in mice treated with MBP-secreting fibroblasts
We have shown previously that treatment of mice suffering from EAE induced by mouse spinal cord homogenate (MSCH) with PLP-secreting fibroblasts can ameliorate disease. 30 In order to determine whether this therapy has more general applicability and is not PLPspecific, transduced fibroblasts secreting an MBP epitope were used to treat MBP protein-induced EAE. A schematic diagram of the MBP construct is shown in Figure 1 . RT-PCR analysis of the MBP-secreting fibroblasts was used to demonstrate the presence of MBPspecific RNA. Female SJL/J mice, 7-week-old, were injected on day 0 with MBP protein in CFA and pertussis toxin, followed by 400 ng pertussis toxin on day 2, and MBP protein in CFA on day 7. The initial EAE attack was observed between days 10 and 14, with the first relapse occurring between days 35-45. Animals with clinical evidence of an acute attack were divided into the following four treatment groups (n ¼ 8): (1) untreated control, (2) MBP-secreting fibroblasts, (3) PLP-secreting fibroblasts, and (4) control enhanced green fluorescent protein (EGFP)-expressing fibroblasts. Animals receiving either MBP-or PLP-secreting fibroblasts exhibited a lower relapse rate (Figure 2a ) and when killed, after the first relapse, had dramatic reductions in inflammatory cells in the brain and spinal cord (Po0.05 for MBPtreated animals, Po0.005 for PLP-treated animals) (Figure 2b ) compared to the two groups of control animals. In particular, mice receiving the PLP-secreting fibroblasts had strikingly reduced lymphocytic infiltration in the brain. Thus, both MBP-and PLP-secreting fibroblasts were capable of successfully treating MBP protein-induced disease.
Change in the leader sequence reduces the effective dose of transduced cells An important aspect in designing an antigen-specific therapy involves efficient production of the antigen. The leader sequence targets a globular protein to the endoplasmic reticulum for eventual constitutive secretion. 36 We hypothesized that a signal sequence derived Gene therapy for murine EAE KA Louie et al from a protein which is secreted, such as a chemokine, may be more efficient at producing product than a leader sequence from a transmembrane protein, H2-L d , which we had previously used in our PLP mini-gene construct (L d -PLP). 30 We, therefore, replaced this signal sequence with that from the secreted protein rat KC chemokine. 37 In order to determine a dose-response for the KC-PLPsecreting fibroblasts, a titration of injected cells was performed. We also compared these results to those obtained when 1x10 5 fibroblasts transduced with the L d -PLP vector were used to treat EAE mice. The data are presented in Figure 3a and demonstrate that injection of either 1 Â 10 6 or 1 Â 10 5 KC-PLP-transduced cells into EAE mice ameliorates disease in marked contrast to 1 Â 10 5 L d -PLP transduced fibroblasts which were ineffective. Thus, we now routinely treat mice by injecting 5 Â 10 5 KC-PLP cells in contrast to the dose of 1 Â 10 7 L d -PLP cells we used in our original studies. 30 In Figure 3b , we present the time course of the mean clinical scores of the mice that either received no fibroblasts or have been treated with 1 Â 10 5 KC-PLP fibroblasts, from the induction of disease to their killing. The results clearly show that the effect of even 1 Â 10 5 PLP-secreting fibroblasts is significant, again confirming the efficacy of the therapy.
Therapy is not cell line-dependent
The LBW cell line used in these studies is an untransformed fibroblast line. In order to ensure that our successful treatment of EAE animals was not cell linedependent, we established a primary line from explanted SJL/J skin. These cells (SJL) were then transduced with KC-PLP-pBIB, selected on blastocidin S, and tested for their ability to treat EAE. We found that SJL cells transduced with KC-PLP-pBIB are as effective as transduced LBW cells; both PLP-secreting cell lines dramatically reduce the number of mice suffering relapses compared to mice treated with control SJL cells transduced with EFGP-pBIB ( Figure 4 ). We can therefore conclude that the effectiveness of our therapy is independent of the fibroblast line used.
Sequestered cells ameliorate EAE
In order to be used in the clinic, a method for discontinuing this therapy, should any exacerbation occur, must be available. To address this issue, we placed the transduced cells within a sealed chamber that was implanted s.c. and which could be rapidly removed by surgery. This chamber is gas and liquid permeable, allowing the transduced cells to remain viable and peptides to be secreted into the surrounding tissue. 38, 39 Mice received either empty implants or implants containing PLP-or EGFP-producing cells on day 24 after disease induction. The data shown in Figure 5 demonstrate that mice implanted with the SJL KC-PLP cells were less likely to relapse than mice implanted with SJL EGFP cells. The chamber alone had no effect on the disease. Removal and staining of chamber sections at the time of killing (42 days post-implantation) show the presence of viable transduced cells within the chamber (Figure 6a, b) . Although we observed some evidence of a mild foreign body tissue reaction, this is a local reaction to the chamber and not immune rejection, since no tissue or perivascular, lymphocytic infiltrate was observed. Using the EGFP cells, we have found that cells continue 
Sequestered allogeneic cells are efficacious in the treatment of EAE
A major advantage of using cells confined within a chamber is the potential ability to use allogeneic cells, thus permitting one therapeutic cell line to be used for all patients. To assess the ability of a PLP-secreting allogeneic cell line to treat EAE in SJL/J mice (H-2 s ), we transduced a primary NOD fibroblast cell line (H-2 g7 ) with either the KC-PLP-pBIB or EGFP-pBIB vectors. We found that PLP-secreting NOD cells are equally effective at treating disease as are the PLP-secreting SJL cells. The results are presented in Figure 7 . NOD cells transduced with EGFP-pBIB had no effect on disease. Thus, we find that by containing the transduced cells within an implant, allogeneic cells can be successfully used in our protocol.
Discussion
Current treatments for MS involving the use of immunocytotoxic drugs or immunomodulatory molecules have only been partially effective. [40] [41] [42] [43] A therapeutic approach which can downregulate pathogenic T cells while leaving the immune response otherwise intact may be an ideal solution. 44 We have previously developed an antigen-specific gene therapy treatment in which fibroblasts, secreting a mini-protein containing an encephalogenic epitope, when injected into EAE mice, cause a dramatic reduction in disease. 30 In the current study, we demonstrate that a second pathogenic epitope, MBP 89-101, is also effective in treating ongoing EAE disease in SJL/J mice. 31 Additionally, we have enhanced our delivery system to address practical and safety concerns which may arise in moving to a clinical setting. By changing the leader sequence, we have been able to increase antigen secretion, thereby reducing the number of cells required for treatment. By sequestering the transduced cells within an implantable chamber, we are able to use allogeneic cells for treatment and we acquire a means of terminating treatment in case of exacerbation.
In recent years, a variety of gene therapy strategies have been used in EAE. [14] [15] [16] [17] [18] One approach has been to genetically modify antigen-specific T cells to deliver immunoregulatory molecules. [45] [46] [47] [48] [49] Direct injection of naked DNA encoding anti-inflammatory cytokines has also been the focus of a significant number of EAE studies.
14 Plasmids encoding the IL-4 gene together with myelin antigen, the PLP (139-151) epitope or myelin oligodendrocyte glycoprotein (MOG) have been shown to elicit either protection in the case of PLP or amelioration of established disease in the case of MOG. 50 The administration of myelin antigen itself to induce immunological tolerance is the strategy we and others have selected using genetically modified cells as the delivery system. B cells transduced with a vector encoding PLP (100-154) as well as B cells expressing a MBP-Ig fusion protein were shown to ameliorate ongoing disease. 51, 52 We have used a diploid, untransformed, transduced fibroblast line secreting PLP (101-157) to successfully treat EAE mice. 30 In addition, our protocol was designed to deliver a low-level, constant exposure to antigen, and this may be the reason we have never observed the anaphylactic response seen in some cases upon repeated injection of antigen. 53 In our previous study, we used the SJL/J model of EAE in which the PLP 139-151 epitope is immunodominant. This appears to be due to the high frequency of PLP 139-151-reactive T cells observed in these mice. 54 In this article we now examine a second epitope, MBP 89-101, in order to determine whether our protocol is PLPspecific or is more generally applicable. We show that by inducing disease with MBP protein (instead of MSCH) we can ameliorate disease using transduced fibroblasts secreting either the MBP 89-101 or PLP 139-151 epitope. These results can be interpreted in light of studies on epitope spreading where induction of EAE with the MBP 84-101 epitope results in the generation of PLP 139-151-specific T cells after the initial attack. 25, 26 Thus, it is not surprising that our PLP-secreting fibroblasts are able to protect MBP-induced EAE mice against relapse by silencing PLP-specific T cells as we have described previously. 30 However, mice receiving the MBP-secreting fibroblasts were also protected from relapse despite the fact that the MBP 84-101 epitope is less encephalogenic than is PLP 139-151. Thus, the secretion of only one epitope can result in the control of disease despite the fact that pathogenic T cells of other specificities are present in sick animals.
We have not yet determined the precise mechanism by which our secreted epitopes silence T cells. However, we do find an increase in IL-2-and INF-g-expressing T cells in the brains of the untreated EAE mice at the time of the first relapse. This contrasts with mice treated with Gene therapy for murine EAE KA Louie et al PLP-secreting fibroblasts who do not relapse and possess T cells generating anti-inflammatory cytokines such as IL-4 and IL-10. 30 Thus, it is not surprising that both PLPand MBP-secreting fibroblasts can treat MBP-induced EAE since our antigen-specific therapy acts through a cytokine-induced pathway. In addition, successful use of the chamber to sequester the transduced cells demonstrates that host T-cell/transduced cell contact is not required. Our working hypothesis is that the secreted mini-protein is presented on the MHC class II molecules of antigen-presenting cells in the absence of co-stimulation, thereby inducing regulatory or suppressor T cells, by a mechanism mediated by anti-inflammatory cytokines. 44 We have never observed any exacerbation of disease upon treatment with transduced fibroblasts. Nevertheless, translation from animal models to humans can have unexpected consequences; [55] [56] [57] [58] [59] [60] [61] therefore, adapting this protocol for human use requires a means of rapidly terminating treatment. We have addressed this concern by confining the transduced cells within a chamber that is implanted s.c. and can be removed surgically. Human studies have already been undertaken utilizing these implants in which parathyroid tissue was successfully sequestered for over a year. 38 In rats, cells transduced with an erythropoietin vector and confined in these chambers express the transgenic protein for more than 12 months. 39 We also find long-term expression of a reporter gene by transduced cells in our murine implants. Histological examination of these chambers, 42 days after implantation, revealed a high degree of vascularization, suggesting that our therapeutic mini-protein can be secreted for long periods of time. In addition, there is no evidence of immune cell infiltrate around the device that could potentially exacerbate autoimmunity. The fact that we can use allogeneic transduced cells greatly enhances the practicality of this protocol since one 'universal' allogeneic cell line can be used to treat patients with diverse MHC haplotypes without the possibility of rejection.
We have demonstrated that our protocol is effective using an MBP epitope as well as the PLP epitope; both are epitopes which are recognized by T cells of many patients with the DR2 haplotype. 33, 35, [62] [63] [64] The fact that we can treat EAE successfully, without the requirement that all epitopes recognized by pathogenic T cells be secreted, suggests that treatment of MS patients need not be individualized despite extensive MHC polymorphism and epitope diversity. In the clinic, initial screening of the myelin-specific T-cell reactivities of the patient may indicate that expressing epitopes other than MBP 84-101 and PLP 139-151 may be more efficacious, and our mini-gene construct has, in fact, been designed as a cassette to facilitate exchange of epitope sequences.
In summary, therefore, as well as addressing practical and safety issues, this study suggests that not all encephalogenic epitopes need to be secreted to silence T cells and treat disease.
Materials and methods
Cell lines
A SJL/J fibroblast line, designated LBW 1B2 (LBW), was obtained from Dr G Dreskler (Uniformed Services University, Bethesda, MD, USA) and grown at 371C, 5% CO 2 in RPMI medium (Mediatech, Herndon, VA, USA) supplemented with 10% FCS (BioWhittaker, Walkersville, MD, USA), 50 U/ml penicillin, 50 mg/ml streptomycin, and 2 mM L-glutamine (all Irvine Scientific, Santa Ana, CA, USA) (RPMI-10). An SJL/J primary cell line (SJL) was established from a dorsal skin explant as detailed in Freshney. 65 It was grown in RPMI supplemented with 20% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mg/ml gentamicin (Sigma, St Louis, MO, USA) and 2 mM L-glutamine (RPMI-20). An NOD/ LtJ primary cell line was derived from embryos as described and grown in RPMI-20. 65 
FACS analysis of primary cell line
The SJL/J primary cell line was analyzed for MHC class II expression using antibody 10-2.16 that recognizes the H2-A s molecule. 66 SJL/J spleen cells were used as a positive control. Antibody 28-14-8 was used as an isotype control. 67 
Vectors
Construction of the mini-gene encoding PLP 101-157 in both the expression plasmid PLP-pRc/CMV and in a retroviral vector (designated L d -PLP) has been described previously. 30 The retroviral expression plasmid PLP-pBIB was generated by subcloning the NcoI-BamHI fragment from PLP-pRc/CMV into the NcoI-BamHI site of pBIB-KMS, an expression vector containing an upstream Kozak eukaryotic translation initiation site 68 and the bsr gene which permits blastocidin-S selection of transductants. 69 To construct the KC-PLP-pBIB vector, two complementary pairs of oligonucleotides coding for the 72 base pair long rat KC chemokine leader sequence 37 were first synthesized and 400 pmol of each complementary oligonucleotide were annealed in 0.02 M Tris, pH 7.2, 0.1 M NaCl, using a Perkin-Elmer 9600 thermocycler programmed to cool from 100 to 601C in 90 min. The two annealing reactions were then combined and returned to the thermocycler and cooled from 60 to 251C in 90 min. The annealed KC leader was digested with BstEII and ApaI and subcloned into PLP-pRc/CMV using the same restriction sites to create the vector KC-PLPpRc/CMV. The retroviral vector KC-PLP-pBIB was then constructed by subcloning the NcoI-BamHI fragment of KC-PLP-pRc/CMV into pBIB-KMS.
The mini-gene encoding MBP (71-111) was generated using synthetic oligonucleotides. Complementary pairs of oligonucleotides were annealed and ligated using standard procedures. The correct MBP product was isolated from the ligation reaction by electroelution from a 7 M urea/8% acrylamide gel. To create the MBP-pRc/ CMV vector, the PLP-pRc/CMV plasmid was digested with ApaI and AflII then run on a 2% agarose gel to remove the PLP mini-gene. The ApaI/AflII-digested vector was eluted from the gel using GeneClean (Bio101, La Jolla, CA, USA) and then ligated to the MBP DNA. The KC leader sequence was cloned into MBP-pRc/CMV as detailed above for the PLP-pRc/CMV construct, generating the vector KC-MBP-pRc/CMV. In order to clone the KC-MBP sequence into pBIB-KMS, a NotI site was introduced into the KC-MBP-pRc/CMV vector downstream of the MBP sequence using a QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) (see Figure 1) . The KC-MBP sequence was then subcloned into pBIB-KMS using NcoI and NotI to create the vector KC-MBP-pBIB.
Transduction of fibroblast cells
Amphotropic retroviral particles carrying the PLP-pBIB, KC-PLP-pBIB, KC-MBP-pBIB, or EGFP-pBIB constructs were produced by transient transfection of the high-titer retroviral helper packaging line, Phoenix-Ampho. 70 For transfections, 0.15 mg of plasmid DNA for each construct was precipitated by the addition of 0.25 M CaCl 2 and Hank's balanced salt solution in a final volume of 150 ml. The precipitated DNA was added dropwise to wells of a six-well plate containing 1.5 ml/well Phoenix-Ampho cells that had been seeded 18 h earlier in DMEM (Mediatech) supplemented with 10% FCS (DMEM-10) at a density of 0.5 Â 10 6 cells/ml. After 6 h at 371C, medium was replaced with fresh DMEM-10. After 24 h, transfected Phoenix-Ampho cells were placed at 321C for 18 h, after which supernatants containing retrovirus were collected, centrifuged to remove cells and stored at À801C. For transduction of the fibroblast cells, a series of two-fold dilutions of target cells starting with 1 Â 10 4 cells/well in 0.5 ml were plated in a 24-well plate 1 day prior to transduction. On the day of transduction, wells which were 1/3-1/2 confluent received undiluted viral supernatant (0.5 ml) and 10 mg/ml DEAE/Dextran (Sigma); control wells received 0.5 ml medium supplemented with DEAE/Dextran. Plates were centrifuged at 1800 r.p.m. for 30 min at 41C, then incubated overnight at 321C in 5% CO 2 . The viral supernatant was then aspirated and replaced with RPMI-10 and the cells were transferred to a 371C, 5% CO 2 incubator. Upon reaching confluency, cells were expanded and grown in selection medium (RPMI-10 supplemented with 10 mg/ml blastocidin S (Calbiochem, La Jolla, CA, USA)).
Analysis of PLP-specific and MBP-specific mRNA expression RNA was isolated from 4 Â 10 6 cells using RNAzol B (Tel-Test, Inc., Friendswood, TX, USA). The final RNA product was resuspended in diethylpyrocarbonate (DEPC)-treated double-distilled (dd)H 2 O. RT-PCR analysis was performed on 1 mg of RNA using the GeneAmp RNA PCR Kit (Perkin-Elmer/ABI). The following primers were used for PLP: 5 0 -GCGACTACAAGACCAC CATCT-3 0 and 5 0 -TAAGGCTAGCATAGGTGATG-3 0 . The MBP-specific primers were 5 0 -GCTAGCCTGCCCCAGA AGTCG-3 0 and 5'-CTTAAGGCCTCTCCCCTTCCCTTG-3'. The RT-PCR product was analyzed on a 1.5% agarose gel and DNA of the correct size was isolated and submitted for automated sequencing.
Induction of EAE in SJL/J mice
Female SJL/J mice (Jackson Laboratory, Bar Harbor, ME, USA), 6-week-old, were each injected with an identification chip (AVID Technology, Norco, CA, USA). To induce EAE using MSCH, 7-week-old mice were injected s.c. on the lower back with 0.7 mg MSCH in CFA on day 0 and boosted on day 7 with the same dose of MSCH in IFA. Typically, the initial EAE attack was observed between days 14 and 18, with full recovery by day 21. The first relapse usually occurred between days 45 and 55.
To induce disease with MBP protein, 7-week-old mice were injected s.c. on the lower back with 0.8 mg bovine MBP protein (Sigma) in CFA and 400 ng pertussis toxin (Sigma) i.p. on day 0, followed by 400 ng pertussis toxin i.p. on day 2, and 0.8 mg MBP protein in CFA on day 7. The initial EAE attack was usually observed between days 10 and 14, with the first relapse occurring between days 35 and 45.
Treatment of EAE mice with retrovirally transduced fibroblasts
Only animals developing clinical disease were used for further study. By day 21 all mice had recovered from their initial attack. Animals were then divided into groups prior to initiation of treatment on day 23 (number of mice per group is indicated in each figure legend). One group of mice comprised the untreated control. Mice receiving treatment with fibroblasts were injected s.c. in the neck/shoulder area. Mice were checked daily and the level of disease was evaluated according to the following scale: 0 ¼ normal; 1 ¼ slow, sluggish; 2 ¼ limp tail; 3 ¼ limp tail, hind limb weakness, waddling gait; 4 ¼ partial hind limb paralysis; 5 ¼ complete hind limb paralysis; 6 ¼ immobile; 7 ¼ moribund. Between days 65 and 70, animals were killed and their brain and spinal cord removed and coded for blinded histological examination.
Treatment of EAE mice with transduced cells sequestered within a chamber TheraCyte 4.5 ml immunoisolation devices (TheraCyte, Irvine, CA, USA) were loaded with transduced fibroblasts (5 Â 10 5 or 2 Â 10 6 cells, depending on the experiment) and sealed according to the manufacturer's protocols. On day 23 post disease induction, mice were anesthetized with avertin (Aldrich, Milwaukee, WI, USA) (0.017 ml/g mouse weight) administered i.p., and the chamber was implanted s.c. on the back. Mice were checked daily for the level of disease as detailed above. Between days 65 and 70, the animals were killed and their brain and spinal cord removed and coded for blinded histological examination. One animal which received an implant containing EGFP-secreting fibroblasts was kept alive until day 77 at which time the implant was removed and examined for the presence of viable cells by fluorescent microscopy.
Histology
Coded sections from the brain and spinal cord were read in blinded fashion and scored according to the following scale: 1+ mild (one to three small foci of inflammation); 2+ moderate (more than three to seven foci containing at least 10 mononuclear cells); 3+ severe (large foci of 15-25 cells with perivascular and meningeal collections); 4+ severe with necrosis (demyelination plus mononuclear cells in 3+ state).
Post-killing, the immunoisolation devices were removed and fixed in 10% formalin, then sectioned and stained using hematoxylin and eosin by DDF Services (Carpentersville, IL, USA).
Statistical analyses
Histological data were analyzed for statistical significance using an unpaired t-test (Graph Pad Prism, Graph Pad Software, Inc., San Diego, CA, USA).
